

## Disclosures

### Personal Commercial (6)

| Company Name                                              | Relationship Category                                                                                | Compensation Level       | Topic Area(s)                      |
|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------|--------------------------|------------------------------------|
| <i>Self</i>                                               |                                                                                                      |                          |                                    |
| Boehringer-Ingelheim                                      | Speaker's Bureau                                                                                     | Significant (>= \$5,000) | Prevention                         |
| Eli Lilly and Company                                     | Speaker's Bureau                                                                                     | Significant (>= \$5,000) | General Cardiology                 |
| Heart IO                                                  | Other - <i>early round investment</i>                                                                | Significant (>= \$5,000) | General Cardiology                 |
| Pfizer Inc                                                | Speaker's Bureau                                                                                     | Modest (< \$5,000)       | General Cardiology                 |
| ScPharma                                                  | Research/Research Grants<br>‡ FED-HF ( <i>Fursoscix Early Discharge Heart Failure Cohort Study</i> ) | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| <i>Spouse/Domestic Partner/Immediate Household Member</i> |                                                                                                      |                          |                                    |
| Cytokinetics                                              | Consultant Fees/Honoraria                                                                            | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name            | Relationship Category                                         | Compensation Level | Topic Area(s) |
|---------------------------------------|---------------------------------------------------------------|--------------------|---------------|
| <i>Self</i>                           |                                                               |                    |               |
| International Cardio-Oncology Society | Other - <i>Co-Chair of the Center of Excellence Committee</i> | None (\$0)         | Other         |

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (1)

| Funding Source                                 | Institutional Compensation Level |
|------------------------------------------------|----------------------------------|
| Investigator Initiated Study ScPharmaceuticals | Significant (>= \$5,000)         |

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

#### Certified Education Attestation | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

#### Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

#### Embargo | Signed on 10/1/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

#### On-Going Obligation Agreement | Signed on 12/18/2025

### ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private

endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.